Loading clinical trials...
Loading clinical trials...
A Multi-Center, Open-Label Trial Investigating Behavior Related to Ella® Use in a Simulated OTC Environment (LIBRella)
Conditions
Interventions
Use Phase (Ulipristal Acetate, 30 mg)
Locations
34
United States
HRA Pharma Investigational Site
Rancho Cucamonga, California, United States
HRA Pharma Investigational Site
Boulder, Colorado, United States
HRA Pharma Investigational Site
Denver, Colorado, United States
HRA Pharma Investigational Site
Denver, Colorado, United States
HRA Pharma Investigational Site
Fort Myers, Florida, United States
HRA Pharma Investigational Site
Miami, Florida, United States
Start Date
May 23, 2017
Primary Completion Date
June 14, 2018
Completion Date
June 14, 2018
Last Updated
December 2, 2022
NCT06162611
NCT03614494
NCT02078414
NCT03395756
NCT04172584
NCT01569737
Lead Sponsor
HRA Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions